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ABS TRACT
In a meta-analysis published by myself and co-authors, we report differences in the life history risk
factors for estrogen receptor negative (ER) and estrogen receptor positive (ER+) breast cancers. Our
meta-analysis did not find the association of ER breast cancer risk with fast life history characteristics
that Hidaka and Boddy suggest in their response to our article. There are a number of possible
explanations for the differences between their conclusions and the conclusions we drew from our
meta-analysis, including limitations of our meta-analysis and methodological challenges in measuring
and categorizing estrogen receptor status. These challenges, along with the association of ER+ breast
cancer with slow life history characteristics, may make it challenging to find a clear signal of ER breast
cancer with fast life history characteristics, even if that relationship does exist. The contradictory results
regarding breast cancer risk and life history characteristics illustrate a more general challenge in
evolutionary medicine: often different sub-theories in evolutionary biology make contradictory
predictions about disease risk. In this case, life history models predict that breast cancer risk should
increase with faster life history characteristics, while the evolutionary mismatch hypothesis predicts that
breast cancer risk should increase with delayed reproduction. Whether life history tradeoffs contribute to
ER breast cancer is still an open question, but current models and several lines of evidence suggest
that it is a possibility.
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Hidaka and Boddy [1] report evidence consistent
with the hypothesis that ER breast cancer risk is
associated with a fast life history strategy. In a meta-
analysis published by myself and co-authors in this
journal, we reported differences in the life history risk
factors for estrogen receptor negative (ER) and
estrogen receptor positive (ER+) breast cancers.
We did not find an association of ER breast cancer
risk with fast life history characteristics. However,
Hidaka and Boddy’s proposal is based on other evi-
dence not included in our meta-analysis, such as
differences in socioeconomic status, nutrition, and
genetic variants that are associated with fertility.
There are a number of possible explanations for
the differences between their conclusions and the
conclusions we drew from our meta-analysis,
including limitations of our meta-analysis and meth-
odological challenges in measuring and
categorizing estrogen receptor status.
The first possibility is that ER breast cancer is
not, in fact, associated with fast life history charac-
teristics, despite Hidaka and Boddy’s review of lit-
erature that supports this association. Although our
meta-analysis showed no association of ER breast
cancer risk with either parity or age of first birth, re-
sults of studies included were not consistent, with
some finding that ER- breast cancer was in fact
associated with higher parity and others finding
the opposite. ER breast cancer is much less com-
mon than ER+ cancer, limiting the statistical power
of many of these studies. The relationship between
ER status and life history characteristics may be
more complex than can be understood with meta-
analyses on existing studies with their own
limitations.
The second potential explanation for the differ-
ences between our results is methodological chal-
lenges in breast cancer categorization. Our meta-
analysis did not detect a relationship between ER
breast cancer and life history characteristics; this may
be because this relationship does not exist or because
of inconsistent categorization of breast cancer into
ER+ and ER- subtypes. ER status is typically decided
based on the cutoff that at least 10% of cells in the
biopsy stain positive for estrogen receptors, but this
is not entirely consistent across studies, and some
recommendations have set the threshold for ER+ as
low as 1% [2]. Further, staining of receptors is accom-
plished using immunohistochemistry methods,
which are subject to a variety of methodological chal-
lenges including variations in tissue preparation,
delay in exposure and length of exposure to
antibodies [3, 4]. A study of 150 laboratories in the
UK found that many local laboratories classified
tumors as having lower ER expression than the UK
central laboratory’s scoring system [4], suggesting
that tumors with relatively high ER expression may
be miscategorized as ER. This means it may be dif-
ficult to find a relationship between ER breast can-
cer risk and fast life history characteristics even if such
a relationship exists. Given our meta-analysis results
which show an association of ER+ breast cancer risk
with slow life history characteristics, ER + tumor that
are categorized as ER- tumors might introduce errors
that limit our capacity to detect an association of ER-
breast cancer with fast life history characteristics.
In addition, the ER breast cancer category is a
combination of HER2+ cancers and triple negative
(estrogen receptor negative, progesterone receptor
negative and HER2 negative) cancers. These tumor
types are qualitatively different, have different sur-
vival outcomes [5] and may have different life history
factor associations. So, even if the ER classification
were accurate, we might expect mixed results from
the ER tumors.
Another methodological challenge in categorizing
breast cancer receptor status arises from tumor het-
erogeneity: when only a single biopsy is taken
sampling error can lead some breast cancers that
may have a large proportion of ER+ cells to be
categorized as ER. If a large number of breast can-
cers are estrogen sensitive, but are categorized as
ER or vice versa, this limits our ability to detect an
association between ER breast cancer and fast life
history strategy. Sampling from multiple regions of
the tumor could help to address this limitation, as
could measuring the proportion of ER+ cells
and using that proportion in analyses of risk factors
(rather than binary categories of ER+/).
Theoretical work completed after this meta-
analysis was published suggests that cancer risk
should be associated with fast life history character-
istics including faster growth, early reproduction
and higher fertility [6]. This theoretical result is not
consistent with our meta-analysis, with the excep-
tion of early menarche, which we found to be
associated with both ER+ and ER breast cancer
risk. We also found in our meta-analysis that
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ER+ breast cancer was associated with slow life his-
tory characteristics, which is likely due to evolution-
ary mismatch between our modern environment
and the environment in which our ancestors
evolved. This is also not consistent with the predic-
tions of this recently published model. The evolu-
tionary mismatch account posits that increased
cancer risk is associated with estrogen exposure
due to modern females having 3–4 times more ovu-
latory cycles than ancestral females. In the absence
of the effects due to evolutionary mismatch, the pre-
dicted pattern of cancer susceptibility being
associated with fast life history strategy [6] might
emerge for breast cancer.
Whether life history tradeoffs contribute to ER
breast cancer is still an open question, but current
models and several lines of evidence suggest that it
is a possibility. Future work using consistent
methods for assessing ER/ER+ status, stratifica-
tion of ER cancers into HER2+ and triple negatives,
analyzing multiple biopsies and conducting ana-
lyses using the proportion of cells staining positive
for ER could help resolve these open questions.
Other important open questions remain regarding
the potential mechanisms that may underlie associ-
ations between life history characteristics and breast
cancer risk, such as alterations in methylation of
tumor suppression genes such as BRCA1 [7], and
the association of fetal microchimerism with differ-
ences between subtypes of breast cancer risk [8, 9].
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